Equity Brief · Healthcare2026-05-20
MRK·Healthcare

Merck & Company Inc

I · Analyse IA

En bref

Merck develops and sells prescription medicines for cancer, vaccines for diseases like HPV and rotavirus, and treatments for diabetes, HIV, and infectious diseases under brands like Keytruda, Gardasil, Januvia, and Bridion [Company Overview]. The company also operates a substantial animal health business selling livestock vaccines, companion animal treatments like Bravecto flea medication, and livestock intelligence solutions through its Allflex brand [Company Overview]. Merck partners with other pharma companies including Daiichi Sankyo, AstraZeneca, and Moderna to co-develop experimental treatments across multiple disease areas [Company Overview].

Merck is a major pharmaceutical company that develops and sells prescription drugs, vaccines, and animal health products worldwide [Yahoo Finance]. Its blockbuster cancer drug Keytruda is a cornerstone revenue driver, and the company recently announced breakthrough Phase 3 trial results for a new cancer treatment targeting endometrial cancer [Yahoo Finance]. With a market cap of $282.2 billion and strong margins, Merck operates as one of the largest drugmakers globally, though it faces typical pharmaceutical risks including patent cliffs and regulatory hurdles [Yahoo Finance].

Merck demonstrates strong profitability and a solid balance sheet with high margins and manageable debt levels [Yahoo Finance].

En bref AI analysisConfiance 8/10

Score Sentinellis

8.4/10

Financially healthy

Capitalisation boursière

$282.2B

Chiffre d'affaires (12 mois)

$64.9B

II · Actualités récentes

Ce qui a fait bouger le cours

6 stories · ranked by relevance

  • macro2026-05-20

    How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results

    Yahoo Finance

  • macro2026-05-20

    Merck and eschbach's PMWS Workshop Accelerates Pharma Execution via the "Intelligent Visual Factory"

    Yahoo Finance

  • macro2026-05-19

    Merck’s Sacituzumab Tirumotecan Data Reframes Outlook For Oncology And Valuation

    Simply Wall St

  • macro2026-05-18

    Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

    Yahoo Finance

  • macro2026-05-18

    How The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology Updates

    Simply Wall St

  • macro2026-05-18

    Should Value Investors Buy Merck KGaA (MKKGY) Stock?

    Zacks

Premium · gratuit avec tout compte

Merck's revenue growth of only 1.2% year-over-year indicates the company is facing headwinds, likely from patent expirations on older drugs or competitive pressure in key therapeutic areas [Yahoo Finance].

1 sur 5 risques dans ce rapport

Risques

5

Opportunités

6

Signaux d'alerte

1

Direction

10

21 autres constats dans le rapport complet — gratuit avec tout compte.

Débloquer l'analyse complète de Merck & Company Inc

Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.

  • 5 risques, 6 opportunités et 1 signal d'alerte — chacun avec sa source
  • Plus de 100 indicateurs financiers avec graphiques et comparaisons
  • Résumés d'actualités complets avec liens vers les sources
  • Équipe dirigeante et rémunération
  • Export PDF pour la lecture hors ligne
Débloquer les 12 constats3 rapports gratuits · sans carte

III · Entreprises similaires

À lire également

Same sector · Healthcare or comparable health

L'ajouter à votre liste ?

Read three companies free. Sans carte.

Obtenir 3 rapports gratuits
Merck & Company Inc (MRK) Analyse d'action en langage clair — Sentinellis